Introduction: Erythropoiesis-stimulating agents and iron are commonly used in patients with
INTRODUCTION
Anemia is common in patients with chronic kidney disease (CKD); severe anemia can reduce quality of life, and increase the risk of cardiovascular (CV) events and mortality [1, 2] . Anemia management is central in care for patients with CKD, and treatment with iron and erythropoiesis-stimulating agents (ESAs) is the standard of care for patients on dialysis. Therapeutic goals include correcting anemia and maintaining stable hemoglobin (Hb) levels. Reduced ESA dose and frequency of administration should also be sought [3, 4] . A recent systematic review and meta-analysis of randomized trials in patients with CKD analyzed data from more than 12,000 patients in 40 trials with the aim of comparing the efficacy and safety of ESAs [5] . The conclusion was that epoetins (epoetin alfa, epoetin beta; darbepoetin alfa, methoxy polyethylene glycol-epoetin beta) were similarly effective for preventing blood transfusion and better than placebo and that currently all ESAs are safe and efficacious with minimal differences between the different formulations in the CKD setting.
Despite well-defined therapeutic goals, maintaining Hb within the desired range is challenging in patients with CKD: many factors, including iron status and comorbidities, influence the response to treatment. Continuous erythropoiesis receptor activator [C.E.R.A. (methoxy polyethylene glycol-epoetin beta)] [6] has a long half-life (134 h), a relatively low binding affinity for the erythropoietin receptor and low systemic clearance, allowing once-monthly (QM) dosing, which may be more convenient for patients compared with
shorter-acting ESAs [6, 7] .
A variety of Phase II and III trials of C.E.R.A. have been conducted in CKD. Data from 13
Phase III trials set up with similar design were pooled for this analysis, each multicenter study set up using similar inclusion and exclusion criteria and trial design to allow analyses to be performed both at the single-study level and using pooled data from multiple studies. Data from individual studies in dialysis-dependent patients with CKD have demonstrated that C.E.R.A. QM maintains stable on-target Hb concentrations with fewer dose adjustments than shorter-acting ESAs [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Pooling data from similar individual studies allows investigating the efficacy and safety of C.E.R.A. in clinically relevant subgroups of patients with CKD, where underlying risk factors can potentially affect patients' response to treatment.
The present pool comprises 13 similarly designed studies investigating the efficacy and safety of C.E.R.A. QM in 2060 dialysis patients. /L or \100 9 10 9 /L, poorly controlled hypertension, myocardial infarction, stroke, severe/unstable coronary artery disease, severe liver disease during the previous 3 months or severe congestive heart failure (New York Heart Association class IV).
Study Design
Patients with chronic renal anemia on dialysis (Table 1) receiving ESA treatment entered a 4-to 8-week screening period, during which mean Hb concentrations were maintained within the study's target range (10-12 or 10.5-13 g/dL).
Patients then entered a 16-week C.E.R.A. dose-titration period followed by an 8-week evaluation period ( Fig. 1 At each study visit, routine laboratory measurements were conducted. Relevant tests known to correlate with ESA response were: transferrin saturation, ferritin, and CRP.
Additionally, an ESA resistance index was computed: the rank of the cumulative ESA dosing in the screening period (before switching to C.E.R.A.) over the rank of the average Hb during the screening period [19, 20] . In most studies NT-proBNP was measured at baseline.
Statistical Methods
This analysis included patients who reached the efficacy evaluation period (intention-to-treat completers).
Average Hb concentrations for a particular period were based on all Hb assessments during that period. If H 0 ,…,H n are taken at timepoints t 0 ,…,t n , the time-adjusted average Hb value per patient (Hb concentration) was calculated by: Hb fluctuation 
RESULTS

Study Population
In total, 2060 patients [mean (SD) age 60.6 (15.6) years, 57.6% male] from 13 studies were included in the analysis. Demographic and baseline characteristics are summarized in epoetin beta, and 28% darbepoetin. Some patients had a change in ESA medication during the screening period, thus numbers add to over 100%. Patients were divided into subgroups as follows: lower/upper Hb target range (n = 935/ n = 1125); male/female (n = 1186/n = 874); \65/C65 years (n = 1090/n = 932); low/high baseline NT-proBNP (n = 975/n = 624); patients with diabetes (n = 535), with cardiac risk factors (n = 565), with vascular risk factors (n = 1675), with no CV risk factors (n = 283). 
Gender
All efficacy outcomes were similar across male and female subgroups (Table 3) .
Age
Achieved Hb concentrations, Hb stability, dose changes required, or C.E.R.A. dose required were not significantly different in patients Table 3 ). The iron status was slightly higher in the low NT-proBNP subgroup than in the high subgroup, while CRP values and ESA resistance index were significantly lower (more favorable) in the low NT-proBNP group than in the high group (Table 4) .
Cardiovascular Risk Factors
Achieved Hb concentrations, Hb stability, required C.E.R.A. dose and dose changes were not significantly different in patients with TSAT values were slightly favorable for the no CV risk group compared with patients with diabetes, cardiac or vascular complications, whereas the opposite was seen for ferritin (Table 5) . Likewise, CRP values were lower for the no CV risk group compared with those with diabetes, cardiac or vascular complications, while a higher resistance index was seen in the no CV risk group (Table 5) . Baseline NT-proBNP levels were significantly lower in the no CV risk group compared with the other subgroups ( (Table 6 ). Overall, patients with pre-existing risk factors also experienced higher AE incidences compared with patients with no CV risk factors (Table 6 ).
In the two highest C.E.R.A. dose quintiles, and in the two lowest Hb quintiles, a slight increase in the rate of cardiac AEs was observed (Fig. 4) . In the highest dose group, the percentage of patients experiencing serious CV AEs (6.3%), thromboembolic AEs (5.1%), and vascular AEs (2.4%) was higher than in all other dose quintiles. Contrastingly, similar frequencies of serious CV, thromboembolic and vascular AEs were recorded across the first four Hb quintiles, and lowest values were observed in the fifth quintile; thus, there was no relationship between baseline the comparison is with no CV risk f NT-proBNP was not measured for all patients AE adverse event, CV cardiovascular, L lower, NT-proBNP N-terminal pro-B-type natriuretic peptide, SAE serious AE, U upper presentation of some of these subgroups [22] and an earlier pooled analysis of safety in both dialysis and non-dialysis patients, which concluded that C.E.R.A. showed an overall safety profile comparable with other ESAs [21] . The favorable efficacy, safety and tolerability profile of C.E.R.A. in the general CKD population had been reported previously [7-12, 15, 16] patients on dialysis, where high baseline NT-proBNP levels predicted higher incidences of cardiac and CV endpoints (5000 ng/mL) [17] .
Moreover, elevated NT-proBNP levels have been revealed as an independent mortality predictor in incident hemodialysis patients [25] . While If ESA therapy is used in patients hyporesponsive to ESA treatment, aiming towards the lower Hb levels of the target range is recommended [3, 26] .
Furthermore, our data showed that chronic elevation of CRP levels was associated with increased thromboembolic and vascular AEs.
This agrees with previous observations that suggest CRP-a marker of inflammationconstitutes an independent risk factor for CV disease [27] . Caution should be used in patients hyporesponsive to ESA treatment having high CRP levels or in those with specific risk factors (especially diabetics) or conditions such as symptomatic limb arteriopathy, stroke or non-symptomatic ischemic heart disease, or cancer [27] . 
